pteridines has been researched along with Asthma in 3 studies
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " For this reason, in a series of preclinical studies, we tested the potential of a recently developed small-molecule inhibitor of these two isoforms, TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol], as a form of anti-inflammatory therapy for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD)." | 7.75 | Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. ( Acevedo, LM; Cheresh, DA; Dellamary, L; Dneprovskaia, E; Doukas, J; Eide, L; Martin, M; Noronha, G; Racanelli-Layton, A; Soll, R; Stebbins, K; Wrasidlo, W, 2009) |
| " For this reason, in a series of preclinical studies, we tested the potential of a recently developed small-molecule inhibitor of these two isoforms, TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol], as a form of anti-inflammatory therapy for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD)." | 3.75 | Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. ( Acevedo, LM; Cheresh, DA; Dellamary, L; Dneprovskaia, E; Doukas, J; Eide, L; Martin, M; Noronha, G; Racanelli-Layton, A; Soll, R; Stebbins, K; Wrasidlo, W, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doukas, J | 1 |
| Eide, L | 1 |
| Stebbins, K | 1 |
| Racanelli-Layton, A | 1 |
| Dellamary, L | 1 |
| Martin, M | 1 |
| Dneprovskaia, E | 1 |
| Noronha, G | 1 |
| Soll, R | 1 |
| Wrasidlo, W | 1 |
| Acevedo, LM | 1 |
| Cheresh, DA | 1 |
| Leung, SY | 1 |
| Niimi, A | 1 |
| Noble, A | 1 |
| Oates, T | 1 |
| Williams, AS | 1 |
| Medicherla, S | 1 |
| Protter, AA | 1 |
| Chung, KF | 1 |
| Mutina, ES | 1 |
1 review available for pteridines and Asthma
| Article | Year |
|---|---|
[Treatment of bronchial asthma].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Bronchitis; C | 1974 |
2 other studies available for pteridines and Asthma
| Article | Year |
|---|---|
Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
Topics: Administration, Intranasal; Aerosols; Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreac | 2009 |
Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling.
Topics: Acetylcholine; Activin Receptors, Type I; Animals; Asthma; Bromodeoxyuridine; Bronchi; Chronic Disea | 2006 |